Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes

BACKGROUND: No targeted immunotherapies reverse type 1 diabetes in humans. However, in a rodent model of type 1 diabetes, Bacillus Calmette-Guerin (BCG) reverses disease by restoring insulin secretion. Specifically, it stimulates innate immunity by inducing the host to produce tumor necrosis factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Faustman, Denise L., Wang, Limei, Okubo, Yoshiaki, Burger, Douglas, Ban, Liqin, Man, Guotong, Zheng, Hui, Schoenfeld, David, Pompei, Richard, Avruch, Joseph, Nathan, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414482/
https://www.ncbi.nlm.nih.gov/pubmed/22905105
http://dx.doi.org/10.1371/journal.pone.0041756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414482/
https://www.ncbi.nlm.nih.gov/pubmed/22905105
http://dx.doi.org/10.1371/journal.pone.0041756

Ejemplares similares